The story · written by opus-5.5,
The change took nineteen weeks. On 19 June 2018 the Home Secretary announced a two-part review of cannabis and its scheduling. On 1 November 2018 regulations signed by the Home Office minister Nick Hurd came into force in England, Wales and Scotland, and cannabis-based medicines could be prescribed without a Home Office licence.
The two reviews
The first part was led by the government’s Chief Medical Adviser, Professor Dame Sally Davies. Her review, published on 3 July, found “conclusive evidence of the therapeutic benefit of cannabis based medicinal products for certain medicinal conditions” and recommended moving the whole class out of Schedule 1, the category for drugs with no recognised medical use.
The second part went to the Advisory Council on the Misuse of Drugs. Its advice of 19 July supported prescription access for products meeting a clear definition, asked for “checks and balances” on prescribing, and held back on synthetic cannabinoids. The Home Secretary accepted that advice.
What the regulations did
They created a legal category, the “cannabis-based product for medicinal use in humans”: a product that contains cannabis, cannabis resin, cannabinol or a cannabinol derivative, is produced for medicinal use in humans, and is a medicinal product or an ingredient of one. That category moved from Schedule 1 to Schedule 2 of the Misuse of Drugs Regulations 2001. The Home Office noted that it was the first time a drug had been rescheduled by its form and purpose as well as its composition.
| Rule (new regulation 16A) | Content |
|---|---|
| Unlicensed “special” products | Only on the prescription or direction of a doctor on the Specialist Register |
| Other routes | A clinical trial, or a product with a marketing authorisation |
| Smoking | Prohibited, except for research |
The memorandum explains the limits by “the very high levels of unlawful recreational use of cannabis” and the need to minimise misuse, harm and diversion. Northern Ireland was to mirror the change in its own legislation.
Why the index moved
Only access changed, by one point, and the total moved from 14 to 15. Before November 2018 the sole lawful cannabis medicine was Sativex, licensed in 2010 and rescheduled in 2013. Afterwards a specialist could prescribe a wider range, including the plant itself in a form that is not smoked. Possession, growing and supply outside a prescription stayed Class B offences, so no other score moved.[1][2]
Score by segment 0 to 10
- Possession · 25%1 → 1
- Personal cultivation · 25%1 → 1
- Punishment & enforcement · 20%3 → 3
- Sharing & gifting · 10%1 → 1
- Consumption · 10%1 → 1
- Legal access · 10%1 → 2+1
The bar shows the score after the change; the tick marks where it stood before. The scores after the change are United Kingdom's current scores.
References
- The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018, S.I. 2018/1055 (legislation.gov.uk)archived
- Home Office — Explanatory Memorandum to S.I. 2018 No. 1055 (legislation.gov.uk, PDF)archived
- BMJ — Medical cannabis, patients turn to private clinics because of NHS void (PDF)
- Wikipedia — Cannabis in the United Kingdomarchived
- Forces of Necessity: Lay Advocacy and the Remedicalization of Cannabis in the UK, 1973–2004Suzanne Taylor · In Cannabis: Global Histories, edited by Lucas Richert, James H. Mills · MIT Press · 2021 · pp. 341–361 · ISBN 9780262366137
Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.